Abstract: Provided are systems, methods, and devices for implementing a corresponding intervention treatment regimen for the respective subject. A corresponding first plurality of responses of the respective subject is received when provided a first questionnaire, which is applied to a set of models to determine a baseline resilience. A corresponding interactive digital journal associated with the respective subject is generated, allowing access to a corresponding intervention treatment regimen. The corresponding interactive digital journal charts a progress through the intervention treatment regimen by capturing a corresponding subjective narration and a corresponding objective feedback based on a corresponding second plurality of responses of the respective subject when provided a second questionnaire during exposure to the respective intervention treatment regimen. The corresponding intervention treatment regimen includes a corresponding plurality of curricula.

Abstract: Disclosed are benztropine analogs having the formula (I) in which Ar is a C6-C20 monocyclic aryl group or a C10-C20 bicyclic aryl group or a heteroaryl, heterocyclic, or arylheterocyclic group having 2 to 12 carbon atoms and one or more heteroatoms selected from the group consisting of N, O, S, P, and any combination thereof; m=1 to 5; n=1 to 3; and R1 to R4 are as described in the specification; or a pharmaceutically acceptable salt or solvate thereof; pharmaceutical compositions and use thereof, e.g., in treating mental disorders.

Abstract: Disclosed are benztropinamine analogs having the formula I (I) in which E is NR1, S, or CH2; B is NR4, O, or CH2; m=1 to 5; n=1 to 3; Ar is a C5-C20 monocyclic aryl group or a C10-C20 bicyclic aryl group or a heteroaryl group having 2 to 6 carbon atoms and one or more heteroatoms selected from the group consisting of N, O, S, and any combination thereof; and bond “a” can be of ?, ?, or ?/? configuration, wherein R1 to R5 are as described in the specification; or a pharmaceutically acceptable salt or solvate thereof; pharmaceutical compositions and use thereof, e.g., in treating mental disorders.

Abstract: Disclosed are benztropine analogs having the formula (I) in which Ar is a C6-C20 monocyclic aryl group or a C10-C20>bicyclic aryl group or a heteroaryl, heterocyclic, or arylheterocyclic group having 2 to 12 carbon atoms and one or more heteroatoms selected from the group consisting of N, O, S, P, and any combination thereof; m=1 to 5; n=1 to 3; and R1 to R4 are as described in the specification; or a pharmaceutically acceptable salt or solvate thereof; pharmaceutical compositions and use thereof, e.g., in treating mental disorders.

Abstract: The present invention provides a family of tropane analogs. More particularly, the present invention provides a family of 4' and 4',4"-substituted-3.alpha.-(diphenylmethoxy)tropane analogs having the formula ##STR1## in which R is a functional group including, but not limited to, hydrogen, alkyl, alkoxy, arylalkyl, aryloxyalkyl, cinnamyl and acyl; and R.sup.1 and R.sup.2 are independently selected and are functional groups including, but not limited to, hydrogen, alkyl, alkoxy, hydroxy, halogen, cyano, amino and nitro. The benztropine analogs of the present invention have a high affinity for the dopamine transporter and inhibit dopamine uptake, but they do not exhibit a cocaine-like behavioral profile. Moreover, the present invention provides methods of using such benztropine analogs to treat cocaine abuse, to image dopamine transporter/cocaine binding sites, and to diagnose and/or monitor neurodegenerative disorders (e.g., Parkinson's disease).